Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesInstil Bio Inc.

Instil Bio Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
6.15 USD -0.16 ( 2.54%)
Last update at 2026-11-12T15:38:00Z
VOLUME
20102
Market Cap
48.90M

Momentum Score

…

Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
6.15
Low
6.33
High
52 Week Price Range
5.67
Low
21.98
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
6.31
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.14M
Debt / Equity
0.75
ROE
-25.33%
Net Debt
78.54M
ROCE
-32.99%
Diluted EPS TTM
-4.24

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -71.37M -74.14M -156.09M -225.25M -156.75M
Net income -71.37M -74.14M -156.09M -223.18M -156.79M
Selling general administrative 27.22M 44.21M 47.55M 62.23M 48.31M
Selling and marketing expenses - - 4.76M - -
Gross profit -0.53M -3.61M -4.76M - -
Reconciled depreciation 0.53M 3.61M 5.82M 5.99M 2.75M
Ebit -65.54M -66.14M -151.87M -226.46M -158.31M
Ebitda -65.01M -62.53M -147.12M -200.20M -155.56M
Depreciation and amortization 0.53M 3.61M 4.76M 26.26M 2.75M
Non operating income net other - - - - -1.20M
Operating income -52.91M -73.54M -159.17M -226.46M -155.56M
Other operating expenses 52.91M 73.54M 159.17M 203.29M 155.56M
Interest expense 5.83M 8.99M 5.21M 1.88M 1.56M
Tax provision - - -0.60M -2.07M 0.04M
Interest income 3.86M 6.99M 8.47M 3.65M -
Net interest income -1.97M -2.00M 4.49M 1.77M -
Income tax expense - - - -2.07M 0.04M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 52.37M 73.54M 159.17M 203.29M 155.56M
Cost of revenue 0.53M 3.61M 4.76M - -
Total other income expense net -18.46M -0.59M 3.08M 1.21M -1.20M
Net income from continuing ops -71.37M -74.14M -197.01M -223.18M -156.79M
Net income applicable to common shares - - - - -156.79M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 203.52M 263.57M 325.63M 482.13M 609.98M
Intangible assets - - - - 10.10M
Other current assets 114.45M 11.15M 8.90M 8.46M 9.92M
Total liab 89.66M 94.13M 99.80M 118.52M 54.78M
Total stockholder equity 113.87M 169.44M 225.83M 363.61M 555.20M
Other current liab 3.69M 5.55M 7.60M 28.05M 35.79M
Common stock - - - - -609.98M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -726.49M -655.12M -580.98M -424.89M -201.72M
Other liab - - - - 13.43M
Good will - - - 0.00M 5.72M
Other assets - - - 1.21M 755.95M
Cash 6.64M 8.80M 10.70M 43.72M 37.59M
Total current liabilities 4.84M 7.90M 10.56M 32.79M 41.36M
Net debt 78.54M 78.08M 75.36M 36.19M -37.59M
Short term debt 0.37M 1.68M 1.75M 2.38M -
Short long term debt total 85.18M 86.89M 86.05M 79.90M -
Other stockholder equity 840.94M 824.78M 807.16M 788.99M 147.02M
Property plant equipment - - - - 122.00M
Total current assets 191.43M 124.47M 160.76M 269.38M 464.02M
Long term investments - 0.00M 23.16M - -
Net tangible assets - - - - 555.20M
Short term investments 69.49M 104.51M 141.16M 217.20M 416.51M
Net receivables 0.85M 2.62M - - 8.14M
Long term debt 84.81M 84.19M 81.43M 72.35M -
Accounts payable 0.78M 0.66M 1.21M 2.36M 5.57M
Accumulated other comprehensive income -0.58M -0.23M -0.35M -0.49M -0.09M
Retained earnings total equity - - - - -201.72M
Non currrent assets other 11.73M 8.76M 0.64M 3.41M 8.14M
Non current assets total 12.09M 139.10M 164.87M 212.75M 145.96M
Capital lease obligations 0.37M 2.70M 4.63M 7.55M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 35.04M 53.97M 59.98M 114.54M -416.56M
Change to liabilities - - - - 15.91M
Total cashflows from investing activities 25.48M 53.97M 41.13M - -474.40M
Net borrowings 0.00M 2.76M 8.08M - -
Total cash from financing activities 7.29M 1.75M 8.08M 71.89M 393.16M
Change to operating activities - - - - 0.50M
Net income -71.37M -74.14M -156.09M -223.18M -156.79M
Change in cash -3.83M -0.06M -33.02M 5.63M -203.67M
Begin period cash flow 10.63M 10.70M 43.72M 38.09M 241.76M
End period cash flow 6.80M 10.63M 10.70M 43.72M 38.09M
Total cash from operating activities -36.62M -55.70M -82.03M -180.16M -122.14M
Issuance of capital stock - - - 0.00M 391.48M
Depreciation 0.53M 3.61M 4.76M 5.99M 2.75M
Other cashflows from investing activities -9.57M 0.87M 1.56M - -
Change to account receivables -3.40M - - - -
Sale purchase of stock - - - - 393.23M
Other cashflows from financing activities -0.17M -1.01M 41.13M 70.34M 54.15M
Change to netincome - - - - 27.54M
Capital expenditures 10.00M 10.00M 20.66M 84.59M 57.83M
Cash flows other operating - - - - -11.55M
Cash and cash equivalents changes - - - - -203.37M
Change in working capital -0.56M -12.61M -9.02M -9.57M 4.36M
Stock based compensation 8.69M 17.26M 18.17M 30.44M 26.20M
Other non cash items 26.09M 10.18M 60.15M 16.15M 0.64M
Free cash flow -36.62M -65.70M -102.69M -264.75M -179.97M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
TIL
Instil Bio Inc.		 -0.16
2.54%		 6.15 - - 54248.82 0.47 43213.95 0.62
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Instil Bio Inc.

Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

3963 Maple Avenue, Dallas, TX, United States, 75219

972 499 3350

https://instilbio.com

17

Name Title Year Born
Mr. Bronson Crouch Chairman & CEO 1973
Dr. Sandeep Laumas M.D. CFO & Chief Bus. Officer 1969
Mr. Timothy L. Moore Chief Operating Officer 1961
Dr. Mark E. Dudley Ph.D. Chief Scientific Officer NA
Ms. Sumita Ray J.D. Chief Legal, Compliance, & Admin. Officer 1974
Dr. Robert Hawkins MBBS, Ph.D. Head of R&D NA
Dr. Sandeep Laumas M.D. CFO & Chief Business Officer 1969
Dr. Robert Hawkins MBBS, Ph.D. Head of Research & Development NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…